# Clinical Trial Protocol
# Iranian Registry of Clinical Trials

11 Jul 2026

## Evaluation of the effectiveness of curcumin in the prevention of contrast induced nephropathy in following coronary Angiography: A randomized controlled Trial

### Protocol summary

**Study aim**
Evaluation of effectiveness of curcumin in preventing nephropathy caused by contrast in coronary angiography

**Design**
Double-blind, randomized, placebo-controlled clinical

**Settings and conduct**
This study is conducted in the cardiac angiography department of Afshar Hospital in Yazd. 60 non-emergency patients who undergo coronary angioplasty, were randomly selected in two groups of 30 people, treated and They are controlled. Both groups will receive the original treatment needed. The pills of both groups (curcumin and placebo) are similar in appearance, and the research student and the patient are not aware of the drug content. Patients are receive placebo or curcuma tablets twelve hours before surgery.

**Participants/Inclusion and exclusion criteria**
Age 18 and above .admitted to Afshar Hospital in Yazd who is undergoing coronary angioplasty as a non-emergency. Not receiving nephrotoxic drugs Not taking medicine containing curcumin in the last month There is no history of allergic reaction following the consumption of oral curcumin. Tolerating the use of oral medications Hospitalization in the cardiac intensive care unit for 2 days Informed consent of the patient himself or his legal guardian, Non-entry criteria Pregnant or lactating mothers Allergy to curcumin

**Intervention groups**
Patients are selected in a random permutation case to receive placebo or curcuma tablets twelve hours before surgery. The curcumin tablet used is from Dineh company with the brand name Curcuma, each tablet contains 450 mg of turmeric rhizome powder and 50 mg of turmeric extract. Daru Nama is made by the pharmaceutical laboratory of Shahid Sadoughi Faculty of Pharmacy and it is similar to curcuma drug in terms of shape, size and color.

**Main outcome variables**
Prevention of contrast- induced nephropathy in coronary angiography

### General information

**Reason for update**

**Acronym**

**IRCT registration information**
IRCT registration number: **IRCT20190911044744N4**
Registration date: **2023-12-11, 1402/09/20**
Registration timing: **registered_while_recruiting**

Last update: **2023-12-11, 1402/09/20**
Update count: **0**

**Registration date**
2023-12-11, 1402/09/20

**Registrant information**

**Name**
Ehsan Mirzaei

**Name of organization / entity**

**Country**
Iran (Islamic Republic of)

**Phone**
+98 35 1820 5885

**Email address**
ehsan.mirzaei.1369@gmail.com

**Recruitment status**
**Recruitment complete**

**Funding source**

**Expected recruitment start date**
2023-12-11, 1402/09/20

**Expected recruitment end date**
2024-01-10, 1402/10/20

**Actual recruitment start date**
empty

**Actual recruitment end date**
empty
**Trial completion date**
empty

**Scientific title**
Evaluation of the effectiveness of curcumin in the prevention of contrast induced nephropathy in following coronary Angiography: A randomized controlled Trial

**Public title**
Evaluation of the effectiveness of curcumin in the prevention of contrast induced nephropathy in following coronary Angiography
**Purpose**
Health service research
**Inclusion/Exclusion criteria**
**Inclusion criteria:**
Age 18 years and older Hospitalized in Afshar Yazd Hospital, who is undergoing coronary angioplasty as a non-emergency. not receiving nephrotoxic drugs. not taking curcumin containing drugs in the past one month and no history of allergic reaction after taking oral curcumin Hospitalization in the cardiac intensive care unit for 2 days Informed consent of the patient himself or his legal guar Informed consent of the patient himself or his legal guardian.
**Exclusion criteria:**
Pregnant or lactating women Allergy to curcumin Receiving nephrotoxic drugs
**Age**
From **18 years** old
**Gender**
Both

**Phase**
3
**Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

**Sample size**
Target sample size: **60**
**Randomization (investigator's opinion)**
Randomized
**Randomization description**
Patients are divided into groups of 30 people and using statistical software;30 people out of 60 patients are completely randomly placed in the treatment group and 30 people in the placebo group. Randomization unit: individual Randomization tool: statistical software
**Blinding (investigator's opinion)**
Double blinded
**Blinding description**
In this study, the participants, the main researcher, the doctors and the person in charge of data collection are kept blind. In this way, the list of people who are going to take medicine or placebo will be provided to the head of the surgery department with a number.
**Placebo**
Used
**Assignment**
Parallel
**Other design features**

## Secondary Ids

empty

## Ethics committees

**1**

**Ethics committee**
**Name of ethics committee**
Ethics Committee of Yazd University of Medical Sciences
**Street address**
Faculty of Pharmacy,Yazd, Shohada gomnam St., Alam Square
**City**
Yazd
**Province**
Yazd
**Postal code**
8915173149
**Approval date**
2023-10-08, 1402/07/16
**Ethics committee reference number**
IR.SSU.MEDICINE.REC.1402.178

## Health conditions studied

**1**

**Description of health condition studied**
Contrast induced nephropathy in following coronary angiography
**ICD-10 code**
N04
**ICD-10 code description**
Nephrotic syndrome

## Primary outcomes

**1**

**Description**
Contrast -induced nephropathy in coronary angiography
**Timepoint**
0-48 hours after surgery
**Method of measurement**
Blood test

## Secondary outcomes

empty

## Intervention groups

**1**

**Description**
Intervention group: recipients of curcuma tablets from

Dineh company receive tablet orally 12 hours before coronary angiography to reduce nephrotoxicity of the contrast material and control renal parameters.

**Category**

Treatment - Drugs

**2**

**Description**

Control group: recipients of a placebo prepared in the pharmacy laboratory of Yazd Faculty of Pharmacy in the same size and color as curcuma tablets 12 hours before coronary angiography, receive the tablet orally to reduce the nephrotoxicity of contrast material and control renal parameters.

**Category**

Placebo

## Recruitment centers

**1**

**Recruitment center**

**Name of recruitment center**
Afshar Hospital

**Full name of responsible person**
Ehsan Mirzaei

**Street address**
Yazd-Jomhouri blvd

**City**
Yazd

**Province**
Yazd

**Postal code**
۸۹۱۷۹۴۵۵۵۶

**Phone**
+98 35 3525 5011

**Email**
Ehsan.Mirzaei.1369@gmail.com

## Sponsors / Funding sources

**1**

**Sponsor**

**Name of organization / entity**
Yazd University of Medical Sciences

**Full name of responsible person**
Farimah MoshkaniFarahani

**Street address**
Yazd Faculty of Pharmacy, Shohada Gomnam St., Alam Square

**City**
Yazd

**Province**
Yazd

**Postal code**
8915173149

**Phone**
+98 35 3626 0001

**Email**
Farimah.Moshkani@gmail.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**
No

**Title of funding source**
Yazd University of Medical Sciences

**Proportion provided by this source**
1

**Public or private sector**
Public

**Domestic or foreign origin**
Domestic

**Category of foreign source of funding**
*empty*

**Country of origin**

**Type of organization providing the funding**
Academic

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**
Yazd University of Medical Sciences

**Full name of responsible person**
Ehsan Mirzaei

**Position**
Assistant Professor

**Latest degree**
Ph.D.

**Other areas of specialty/work**
Medical Pharmacy

**Street address**
Yazd Faculty of Pharmacy, Shohada Gomnam St., Alam Square

**City**
Yazd

**Province**
Yazd

**Postal code**
8915173149

**Phone**
+98 35 3820 3419

**Email**
Ehsan.Mirzaei.1369@gmail.com

**Web page address**

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**
Yazd University of Medical Sciences

**Full name of responsible person**
Ehsan Mirzaei

**Position**
Assistant Professor

**Latest degree**
Ph.D.

**Other areas of specialty/work**
Medical Pharmacy

**Street address**

Yazd Faculty of Pharmacy, Shohada Gomnam St., Alam Square

**City**
Yazd

**Province**
Yazd

**Postal code**
8915173149

**Phone**
+98 35 3820 3419

**Email**
Ehsano.Mirzaei.1369@gmail.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**
Yazd University of Medical Sciences

**Full name of responsible person**
Farimah Moshkani Farahani

**Position**
Student

**Latest degree**
Medical doctor

**Other areas of specialty/work**
Medical Pharmacy

**Street address**
Yazd Faculty of Pharmacy, Shohada Gomnam St., Alam Square

**City**
Yazd

**Province**
Yazd

**Postal code**
8915173149

**Phone**
+98 35 3820 3419

**Email**
Farimah.Moshkani@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**
Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**
Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**
Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**
No - There is not a plan to make this available

**Clinical Study Report**
Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**
Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**
Undecided - It is not yet known if there will be a plan to make this available